dc.contributor.author | van Wamel, A | |
dc.contributor.author | Sontum, PC | |
dc.contributor.author | Healey, A | |
dc.contributor.author | Kvåle, S | |
dc.contributor.author | Bush, N | |
dc.contributor.author | Bamber, J | |
dc.contributor.author | de Lange Davies, C | |
dc.date.accessioned | 2017-04-03T10:14:39Z | |
dc.date.issued | 2016-08-28 | |
dc.identifier.citation | Journal of controlled release : official journal of the Controlled Release Society, 2016, 236 pp. 15 - 21 | |
dc.identifier.issn | 0168-3659 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/550 | |
dc.identifier.eissn | 1873-4995 | |
dc.identifier.doi | 10.1016/j.jconrel.2016.06.018 | |
dc.description.abstract | Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice. | |
dc.format | Print-Electronic | |
dc.format.extent | 15 - 21 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE BV | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Cell Line, Tumor | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Mice | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Paclitaxel | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Drug Delivery Systems | |
dc.subject | Male | |
dc.subject | Drug Liberation | |
dc.subject | Ultrasonic Waves | |
dc.subject | Albumin-Bound Paclitaxel | |
dc.title | Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-06-09 | |
rioxxterms.versionofrecord | 10.1016/j.jconrel.2016.06.018 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2016-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Journal of controlled release : official journal of the Controlled Release Society | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Ultrasound & Optical Imaging | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Ultrasound & Optical Imaging | |
pubs.publication-status | Published | |
pubs.volume | 236 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Ultrasound & Optical Imaging | |
dc.contributor.icrauthor | Bamber, Jeffrey | |